Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA is dated May 17, 2022. The report serves to disclose the filing of an updated base prospectus for the Company's €10 billion European Medium-Term Note Program with the Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, or liquidity figures for the reporting period. The document references the inclusion of audited consolidated financial statements for Fresenius Medical Care Holdings, Inc. (FMCH) and its subsidiaries for the years ended December 31, 2021, and 2020, as Exhibit 99.1, but does not summarize the numerical data within the body of this report.
Material Changes
No material changes to financial performance or operations are detailed in this specific filing text. The primary update concerns the regulatory approval of the debt program prospectus.
Guidance, Outlook, and Risks
- Debt Program: Notes issued under the €10 billion program are guaranteed by Fresenius Medical Care Holdings, Inc. (FMCH).
- US Restrictions: Notes under the program may not be offered or sold in the United States absent registration under the US Securities Act of 1933 or an applicable exemption. They will not be offered to "US persons" as defined in Regulation S.
- Availability: The referenced FMCH financial statements are available on the Luxembourg Stock Exchange website and the Company's website.
Investor Verification Checklist
- Verify the specific financial figures in the audited consolidated financial statements of FMCH for 2021 and 2020 (Exhibit 99.1), as they are not summarized in this text.
- Confirm the terms and conditions of the €10 billion European Medium-Term Note Program via the updated base prospectus filed with the CSSF.
- Review the guarantee structure provided by Fresenius Medical Care Holdings, Inc.